Eli Lilly, Drug Prices & Medicare Spending

Eli Lilly manufactures 21 drugs tracked by Medicare Part D with total spending of $17.8B.

Drugs Tracked

$17.8B

Medicare Spending

$234.65

Avg Cost/Claim

86%

Have Generics

Eli Lilly Drugs, Ranked by Medicare Spending

#	Drug	Generic Name	Cost/Claim	Medicare Spending	YoY Change	Generic?
1	Trulicity	Dulaglutide	$473.00	$4.2B	-4.8%	No
2	Mounjaro	Tirzepatide	$673.00	$2.5B	+312.4%	No
3	Verzenio	Abemaciclib	$5,628.00	$1.8B	+32.1%	Yes
4	Humalog	Insulin Lispro	$142.00	$1.6B	-22.7%	Yes
5	Zepbound	Tirzepatide (weight)	$867.00	$1.5B	0.0%	Yes
6	Taltz	Ixekizumab	$3,546.00	$1.2B	+12.6%	Yes
7	Basaglar	Insulin Glargine (biosimilar)	$130.00	$845.0M	-12.1%	No
8	Emgality	Galcanezumab	$688.00	$678.0M	+14.8%	Yes
9	Forteo	Teriparatide	$1,337.00	$567.0M	-18.4%	Yes
10	Olumiant	Baricitinib	$3,677.00	$456.0M	+24.8%	Yes
11	Retevmo	Selpercatinib	$14,375.00	$345.0M	+56.3%	Yes
12	Lyumjev	Insulin Lispro-aabc	$278.00	$345.0M	+18.6%	Yes
13	Humatrope	Somatropin	$2,331.00	$345.0M	-12.4%	Yes
14	Cymbalta	Duloxetine	$19.00	$234.0M	-42.3%	Yes
15	Strattera	Atomoxetine	$189.00	$234.0M	-28.4%	Yes
16	Duloxetine	Duloxetine Hydrochloride	$21.00	$234.0M	-24.6%	Yes
17	Jaypirca	Pirtobrutinib	$13,000.00	$234.0M	0.0%	Yes
18	Reyvow	Lasmiditan	$206.00	$178.0M	+24.6%	Yes
19	Olanzapine	Olanzapine	$30.00	$145.0M	-28.4%	Yes
20	Effient	Prasugrel	$142.00	$123.0M	-18.6%	Yes
21	Fluoxetine	Fluoxetine Hydrochloride	$10.00	$89.0M	-24.6%	Yes

Frequently Asked Questions

Eli Lilly manufactures 21 drugs tracked by Medicare Part D, with total annual spending of $17.8B.

Retevmo (Selpercatinib) is the most expensive at $14,375.00 per claim.

18 of 21 Eli Lilly drugs (86%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.

this entity is one of the data points covered by this site’s U.S. Medicare prescription-drug pricing dataset. The detail above comes directly from CMS Medicare Part D Drug Spending data; the context that follows situates the headline numbers against the broader distribution across U.S. prescription drugs.

The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. prescription drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.

Source: CMS Medicare Part D Spending, 2026.